ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DVAX Dynavax Technologies Corp

11.64
0.00 (0.00%)
Pre Market
Last Updated: 10:12:03
Delayed by 15 minutes
Share Name Share Symbol Market Type
Dynavax Technologies Corp NASDAQ:DVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.64 11.65 11.99 0 10:12:03

Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021

21/07/2021 9:02pm

PR Newswire (US)


Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Dynavax Technologies Charts.

EMERYVILLE, Calif., July 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Wednesday, August 4, 2021 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.  Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 9970706.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

Cision View original content:https://www.prnewswire.com/news-releases/dynavax-to-report-second-quarter-2021-financial-results-and-host-conference-call-on-august-4-2021-301338367.html

SOURCE Dynavax Technologies

Copyright 2021 PR Newswire

1 Year Dynavax Technologies Chart

1 Year Dynavax Technologies Chart

1 Month Dynavax Technologies Chart

1 Month Dynavax Technologies Chart

Your Recent History

Delayed Upgrade Clock